Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases DOI
Ram W. Sabnis

ACS Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 16(1), P. 8 - 9

Published: Dec. 9, 2024

Provided herein are novel TYK2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, processes for preparing compounds.

Language: Английский

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors DOI Creative Commons
Mohammed Hawash

Cells, Journal Year: 2024, Volume and Issue: 13(19), P. 1656 - 1656

Published: Oct. 6, 2024

Protein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer. The implementation protein kinase inhibitors has significantly transformed cancer therapy by modifying treatment strategies. These received substantial FDA clearance recent decades. emerged as primary objectives for therapeutic interventions, particularly context treatment. At present, 69 therapeutics been approved that target approximately 24 kinases, which are specifically prescribed neoplastic illnesses. novel agents inhibit certain such receptor protein-tyrosine protein-serine/threonine dual-specificity nonreceptor kinases. This review presents a comprehensive overview targets inhibitors, with specific focus on cyclin-dependent (CDKs) epidermal growth factor (EGFR). majority reviewed studies commenced an assessment cell lines concluded biological evaluation individual targets. articles provide detailed information structural features potent anticancer activity, refers ability selectively cancer-promoting including CDKs EGFR. Additionally, latest FDA-approved targeting these enzymes were highlighted accordingly.

Language: Английский

Citations

5
Encrypting Cancer&#8217;s Morse Code: The Synergistic Power of CD47-SIRP<i>&#945;</i> Blockade and Tyrosine Kinase Inhibition DOI Open Access

Mahamud Hirsi,

Yahya Lahrach,

Abdirahman Mohamud Abdirahman

et al.

International Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 16(02), P. 135 - 153

Published: Jan. 1, 2025

Language: Английский

Citations

0
Mps1 kinase functions in mitotic spindle assembly and error correction DOI Creative Commons
Víctor M. Bolaños-García

Trends in Biochemical Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

HighlightsMps1 promotes mitotic checkpoint complex assembly and the establishment of bioriented chromosome attachment to spindle microtubules.Mps1 is a multidomain protein kinase that harbors motifs mediating its function in SAC. These are highly conserved during evolution, but with some important deviations species specific.The molecular description Mps1 roles SAC signaling error correction has enhanced our understanding mechanisms govern cell division. Defects division result gross segregation errors genome instability.Inhibition catalytic activity interfere mitosis progression tumor cells promising therapeutic window for treatment aggressive types cancer.Mps1 may also be suitable target infections caused by diverse pathogens, such as fungi.AbstractThe (also known TTK) central component (SAC), an essential self-monitoring system eukaryotic cycle ensures accurate delaying onset anaphase until all chromosomes properly on spindle. upstream regulator recruitment kinetochores critical initiating signaling. This review discusses current functions SAC, emerging details role safeguard stability, potential inhibition cancer associated aberrant defects.

Language: Английский

Citations

0
Targeting TGF-β: a promising strategy for cancer therapy DOI

Himani Rathi,

Charanjit Kaur,

Rajesh Kumar

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: March 28, 2025

Language: Английский

Citations

0
Impact of Tyrosine Kinase Inhibitors on the Expression Pattern of Epigenetic Regulators DOI Open Access
Kinga Tóth, Zsuzsanna Gaál

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1282 - 1282

Published: April 10, 2025

Background: Advances in molecular genetic diagnostics and emerging opportunities for targeted treatment have opened new horizons precision oncology. Tyrosine kinase inhibitors (TKI) are the subgroup of these agents with which most clinical experience has been gathered so far. However, little data is available on effect TKI expression levels molecules responsible epigenetic regulation. Methods: In this study, we investigated vitro vivo tyrosine inhibitor regulators hematological malignancies solid tumors, based included functional genomics repository Gene Expression Omnibus. Results: Statistical analysis datasets series gene patterns revealed numerous significant changes writers, erasers, microRNAs members chromatin-remodeling complexes following treatment. Previously published about role modifiers malignant diseases also summarized. Conclusions: Our results may contribute to establishment novel strategies aiming at combinatorial administration epidrugs cancer, leading less toxic therapy further improved results.

Language: Английский

Citations

0
Layer-by-layer fabrication of covalent organic frameworks on stainless steel needles as solid-phase microextraction probe coupled with electrospray ionization mass spectrometry for enrichment and determination of tyrosine kinase inhibitors in biosamples DOI
Heming Li,

Xinye Shi,

Hang Su

et al.

Journal of Chromatography A, Journal Year: 2024, Volume and Issue: 1733, P. 465276 - 465276

Published: Aug. 15, 2024

Language: Английский

Citations

3
Analytical quality by design-compliant development of quantitative 1H- and 19F-nuclear magnetic resonance methods for the analytical evaluation of the anti-cancer drug, sorafenib DOI

Marwa H. Hassan,

Reham A. I. Abou‐Elkhair, Abdalla E. A. Hassan

et al.

Microchemical Journal, Journal Year: 2024, Volume and Issue: unknown, P. 112544 - 112544

Published: Dec. 1, 2024

Language: Английский

Citations

3
Synthesis and anti-tumor activity of new benzofuran-based chalcone derivatives as potent VEGFR-2 inhibitors DOI

Chunfei Zhang,

Yixin Liu, Xiao Zhang

et al.

RSC Medicinal Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Cancer is one of the most significant public health problems worldwide, and discovery development efficient VEGFR-2 inhibitors has been a research hotspot in cancer treatment. In present work, series novel benzofuran-based chalcone derivatives have prepared,

Language: Английский

Citations

2
Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes DOI Creative Commons
Robert B. Kargbo

ACS Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 15(9), P. 1446 - 1448

Published: Aug. 21, 2024

The continuous evolution of cancer therapy has driven the exploration novel strategies to improve treatment specificity and efficacy while minimizing adverse effects. This article examines two innovative approaches that offer new directions in targeting cells. first approach focuses on developing antibodies specifically bind peptide/major histocompatibility complex (MHC) complexes, enhancing precision effectiveness immunotherapy. second introduces quinazoline compounds target inhibit critical tyrosine kinases progression. Together, these advancements represent promising strides quest develop more effective precise therapies, offering avenues for treating resistant aggressive forms cancer.

Language: Английский

Citations

0
Star wars against leukemia: attacking the clones DOI Creative Commons
Monika M. Toma, Tomasz Skórski

Leukemia, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 2, 2024

Abstract Leukemia, although most likely starts as a monoclonal genetic/epigenetic anomaly, is polyclonal disease at manifestation. This nature results from ongoing evolutionary changes in the genome/epigenome of leukemia cells to promote their survival and proliferation advantages. We discuss here how genetic and/or epigenetic aberrations alter intracellular microenvironment individual clones extracellular selects best fitted clones. dynamic composition makes designing an effective therapy challenging task especially because often display substantial differences response treatment. Here, we novel therapeutic approach employing single cell multiomics identify eradicate all patient.

Language: Английский

Citations

0